Uploaded September 2026 | Updated September 2026, 2 days ago
On August 27, 2026 Ai2 announced a new partnership with the Paul G. Allen Research Center (PARC) at Providence Swedish Cancer Institute to apply Ai2’s AI-powered scientific discovery platform, AutoDiscovery across cancer research datasets.
This partnership represents an important milestone for AutoDiscovery as it moves beyond public research datasets into active cancer research programs at a leading oncology research center. It’s a particularly significant deployment given the high standard required for AI adoption in biomedical science, where every finding must be transparent, reproducible, and independently validated before informing future research.
This event hosted at Ai2 in Seattle, presents that work and explores some of the tough issues surrounding AI deployment in the biomedical sphere.
On August 27, 2026 Ai2 announced a new partnership with the Paul G. Allen Research Center (PARC) at Providence Swedish Cancer Institute to apply Ai2’s AI-powered scientific discovery platform, AutoDiscovery across cancer research datasets.
This partnership represents an important milestone for AutoDiscovery as it moves beyond public research datasets into active cancer research programs at a leading oncology research center. It’s a particularly significant deployment given the high standard required for AI adoption in biomedical science, where every finding must be transparent, reproducible, and independently validated before informing future research.
This event hosted at Ai2 in Seattle, presents that work and explores some of the tough issues surrounding AI deployment in the biomedical sphere.
